Quotes: US MENA   Enter Symbol: NewsLetter: Search: advanced

MMRGlobal Receives Cancer-Fighting Anti-CD20 Monoclonal Antibodies Patent in Korea  Join our daily free Newsletter

MENAFN - - 1/31/2014 8:35:16 AM

Add to Mixx!

(Menafn - Marketwired via COMTEX)

MMRGlobal Receives Cancer-Fighting Anti-CD20 Monoclonal AntibodiesPatent in Korea

LOS ANGELES, CA, Jan 31, 2014 (Menafn - Marketwired via COMTEX) --MMRGlobal, Inc. (otcqb:MMRF) ("MMR"), a leading provider ofPersonal Health Records (PHRs), MyEsafeDepositBox storage solutionsand electronic document management and imaging systems for healthcareprofessionals, today announced that the Company has receivedconfirmation of its first issued patent application for its cancerfighting anti-CD20 monoclonal antibodies in South Korea. This is thefourth country to issue this patent as a result of the ExpeditedPatent Allowance Program which follows the issuance of U.S. patentsto MMR for its anti-CD20 monoclonal antibodies. The South Koreanpatent will be issued under the title "Antibodies and Methods ForMaking and Using Them." The Company also reported that an additionaldivisional South Korean patent application No. 10-2013-7022383 wasfiled on August 23, 2013 which case remains pending. The issuance ofU.S. Patent No. 8,465,741 on June 18, 2013 provided the Company withthe mechanism to request expedited examination of the equivalentpatent claims in numerous international markets. The filings are partof MMRGlobal's plan to expand the scope of its biotech assets andother intellectual property, in particular, the Company's issued U.S.Patent No. 8,465,741 directed at its anti-CD20 antibody assets, whichhas also been granted in Mexico and Australia. MMR also holdsadditional patents pertaining to its B-cell idiotype vaccineworldwide.

The Company's strategy of filing divisional patent applications incountries of commercial interest like China, Japan and South Korea isallowing it to take advantage of an international treaty to expeditereceiving patents based on existing approvals in the U.S. The newestpatent and patent application will help provide additional protectionof the Company's specific antibodies that have particular utility infighting cancers. MMR's anti-CD20 monoclonal antibodies are importantassets of the Company, the value and benefit of which aredemonstrated by how these antibodies are used commercially inproducts like Rituxan(R), an anti-CD20 monoclonal antibody which isdue to go off patent in 2015. Additional patent applications for theCompany's antibodies are also pending in a number of other countriesor regional authorities including Brazil, Canada, China, Hong Kong,India, Europe, and Japan, with additional patent applications inAustralia and South Korea. The Company's anti-CD20 antibodies weredeveloped to help provide low-cost alternatives for treatments likeRituxan(R) in connection with non-Hodgkin's lymphoma and othercancers widely considered too expensive for the world population ofpatients who need costlier forms of treatment to live.

MMRGlobal, through its wholly owned subsidiary MyMedicalRecords,Inc., also owns numerous health information technology patents issuedor pending related to providing online medical and Personal HealthRecords in 12 countries or regional authorities of commercialinterest. These include the U.S., where MMR has 10 issued patents andover 400 claims as well as additional applications and continuationapplications, Australia, Singapore, New Zealand, Mexico, Canada,China, Hong Kong, Japan, South Korea, Israel, and Europe. MMR alsohas hundreds of claims either pending or published related to healthIT worldwide.

In biotech, the Company has invested more than 100 million inresearch and development on its FavId(TM) vaccine trials and use ofcustomized tumor cells to treat lymphoma patients and othertechnologies. MMR has continued to make progress in protecting theCompany's IP, including its anti-CD20 antibodies and B-Cell vaccinepatents entitled "Method and Composition for Altering a B-CellMediated Pathology," which relate to methods of manufacturingcompositions for B-Cell vaccines used in the fight against lymphomaand potentially other forms of cancer.

The anti-CD20 antibodies were part of a portfolio of biotech assetsand other intellectual property originally spun off from the SidneyKimmel Cancer Center. The Company has an active biotech licensingprogram and has already signed licensing agreements worth in excessof twelve million dollars from which it has received nearly onemillion dollars. Although MMRGlobal continues working to license andotherwise exploit an extensive portfolio of biotech assets, includingdata from vaccine trials, thousands of patient tumor samples andother intellectual property, it remains focused on its primary healthIT business.

About MMRGlobal MMRGlobal, Inc., through its wholly-owned operatingsubsidiary, MyMedicalRecords, Inc., provides secure and easy-to-useonline Personal Health Records ("PHRs") and electronic safe depositbox storage solutions, serving consumers, healthcare professionals,employers, insurance companies, financial institutions, retailpharmacies, and professional organizations and affinity groups. TheMyMedicalRecords PHR enables individuals and families to access theirmedical records and other important documents, such as birthcertificates, passports, insurance policies and wills, anytime fromanywhere using the Internet. MyMedicalRecords is built onproprietary, patented technologies to allow documents, images andvoicemail messages to be transmitted and stored in the system using avariety of methods, including fax, phone, or file upload withoutrelying on any specific electronic medical record platform topopulate a user's account. The Company's professional offering,MMRPro, is designed to give physicians' offices an easy andcost-effective solution to digitizing paper-based medical records andsharing them with patients through an integrated patient portal.Through its merger with Favrille, Inc. in January 2009, the Companyacquired intellectual property biotech assets that include anti-CD20antibodies and data and samples from its FavId(TM)/Specifid(TM)vaccine clinical trials for the treatment of B-Cell Non-Hodgkin'slymphoma. To learn more about MMRGlobal, Inc. visitwww.mmrglobal.com. View demos and video tutorials of the Company'sproducts and services at www.mmrtheater.com.

Forward-Looking Statements All statements in this press releasethat are not strictly historical in nature, including, withoutlimitation, intellectual property enforcement actions, infringementclaims or litigation, intellectual property licenses, and futureperformance, management's expectations, beliefs, intentions,estimates or projections, constitute "forward-looking statements."Such forward-looking statements involve known and unknown risks,uncertainties and other factors that may cause the Company's actualresults to be materially different from historical results or fromany results expressed or implied by such forward-looking statements.Some can be identified by the use of words (and their derivations)such as "need," "possibility," "potential," "intend," "offer,""development," "if," "negotiate," "when," "begun," "believe,""achieve," "will," "estimate," "expect," "maintain," "plan," and"continue," or the negative of these words. Actual outcomes andresults of operations and the timing of selected events may differmaterially from the results predicted, and any reported resultsshould not be considered as an indication of future performance. Suchstatements are necessarily based on assumptions and estimates and aresubject to various risks and uncertainties, including those relatingto the possible invalidity of the underlying assumptions andestimates and possible changes or developments in economic, business,industry, market, legal and regulatory circumstances and conditionsand actions taken or omitted to be taken by third parties, includingcustomers, suppliers, business partners, potential licensees,competitors and legislative, judicial and other governmentalauthorities and officials. Factors that could cause or contribute tosuch differences include, but are not limited to: unexpected outcomeswith respect to intellectual property enforcement actions, claims ofintellectual property infringement and general intellectual propertylitigation; our ability to maintain, develop, monetize and protectour patent portfolio for both the Company's health IT andbiotechnology intellectual property assets in the U.S. andinternationally; the timing of milestone payments in connection withlicensing our intellectual property; our ability to establish andmaintain strategic relationships; changes in our relationships withour licensees; the risk the Company's products are not adopted orviewed favorably by the healthcare community and consumer retailmarket; business prospects, results of operations or financialcondition; risks related to the current uncertainty and instabilityin financial and lending markets, including global economicuncertainties; the timing and volume of sales and installations; thelength of sales cycles and the installation process; the market'sacceptance of new product and service introductions; competitiveproduct offerings and promotions; changes in government laws andregulations and future changes in tax legislation and initiatives inthe healthcare industry; undetected errors in our products; thepossibility of interruption at our data centers; risks related tothird party vendors; risks related to obtaining and integratingthird-party licensed technology; risks related to a security breachby third parties; risks associated with recruitment and retention ofkey personnel; other litigation matters; uncertainties associatedwith doing business internationally across borders and territories;and additional risks discussed in the Company's filings with theSecurities and Exchange Commission. The Company is providing thisinformation as of the date of this release and, except as required byapplicable law, does not undertake any obligation to update anyforward-looking statements contained in this release as a result ofnew information, future events or otherwise.


Michael Selsman
Public Communications Co.
(310) 922-7033

SOURCE: MMRGlobal, Inc.


International Provider
Apr 19, 2014 5 Works By Distinguished Author Joyce Carol Oates, University Wire
Apr 19, 2014 ICICI Bank's Touch Banking Branches Cross 100, GlobeNewswire
Apr 19, 2014 Japan to keep whaling in Pacific but with fewer catches, EFE News Services
Apr 19, 2014 EQUITY ALERT: The Rosen Law Firm Files Securities Fraud Class Action Against GrowLife, Inc. -- PHOT, GlobeNewswire
Apr 19, 2014 Rosen Law Firm Files Class Action on Behalf of Shareholders of ChinaCast Education Corporation -- CAST, GlobeNewswire
Apr 19, 2014 Pool Corporation to Present at the 18th Annual Burkenroad Reports Investment Conference, GlobeNewswire
Apr 19, 2014 THE MEDICINES COMPANY 96 HOUR DEADLINE ALERT: Approximately 96 Hours Remain; Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors of Deadline in Securities Class Action Lawsuit Against the Medicines Company - MDCO, GlobeNewswire
Apr 18, 2014 A.A. Milne society puts on "�The Ugly Duckling", University Wire
Apr 18, 2014 Record Store Day and the Vinyl Revival, University Wire
Apr 18, 2014 Allen Claims ECAC Division II All-Star Accolades, University Wire




Middle East North Africa - Financial Network

MENAFN News Market Data Countries Tools Section  

Middle East North Africa - Financial Network

Main News
News By Industry
News By Country
Marketwatch News
UPI News
Comtex News

IPO News
Islamic Finance News
Private Equity News

How-To Guides
Technology Section

Travel Section

Search News

Market Indices
Quotes & Charts

Global Indices
Arab Indices

US Markets Details


Oil & Energy

Currencies Cross Rates
Currencies Updates
Currency Converter

USA Stocks
Arab Stocks

Saudi Arabia 

Investment Game
Economic Calendar
Financial Glossary

Portfolio Tracker


Financial Calculators

RSS Feeds [XML]

Corporate Monitor


Real Estate
Submit Your Property

Arab Research
Buy a Research

Press Releases
Submit your PR

Join Newsletters

© 2000 menafn.com All Rights Reserved.  Terms of Service | Privacy Policy | Contact Us | Advertise | About MENAFN | Career Opportunities | Feedback | Help